Hello **«** You Are Here: Frotocol 1.0 General Information **Creating New: Study** ◀ Go to forms menu Help 1.0 General Information This is the first step in your IRB Application. As you complete this application, you will automatically be guided to the appropriate sections needed to complete your submission. The questions with a red asterisk (\*) are required and must be answered – you will not be able to move to the next page in the application form until you answer any questions that are required. 1. \* Full Study Title: 2. \* Short Study Title: (Limit to 25 characters. This short title will appear with the IRB number for tracking within AURA) 3. \* Principal Investigator: 4. Primary Contact: 5. Co-Investigators: Last First Division Department **Affiliate CNetID UChicago** Name Name ID **UCHAD** There are no items to display 6. Other Study Staff: First Division **Affiliate CNetID UChicago** Last Department Name Name ID **UCHAD** There are no items to display Exit ■ Save Continue 🗪

1 of 1

|   |              |  |                               |                                    |                                  |           |         |  | Hello  | •                               |
|---|--------------|--|-------------------------------|------------------------------------|----------------------------------|-----------|---------|--|--|---------------------------------|
| ■ Validate                                  | <b>≪</b> You | Are Here: 🔓 short test tii               | ile 2025                      |                                    |                                  |           |         |  |  |                                 |
| ▼ General Info and Staff                    | Fo           | diting: IRB25-0                          | ) <u>0</u> 04                 |                                    |                                  |           | 4 (     | Go to forms me                                     | nu 🔒 Print 🕶   | ? Help                          |
| 1.0 General<br>Information                  | 100          | itting. Ittb20 (                         | 7004                          |                                    |                                  |           | •       | 30 to lomis me                                     | iiu <b>—</b> Friiii.▼                                  | Help                            |
| BSD 1.2<br>Research Team<br>Details         |              | Research Team Detail                     | _                             | v support ar                       | oup?                             |           |         |  |  |                                 |
| BSD 1.4 Funding<br>Source                   |              |  | •                             |                                    |                                  |           |         |  |  |                                 |
| BSD 1.5 Study<br>Locations  ▼BSD            | 2            | 2. <b>Select the checkbox fo</b><br>Role | Person                        | Division                           | e obtaining cor<br>Department    | Affiliate | Consent | CITI<br>Human<br>Subjects<br>Training<br>Completed | Non-CITI<br>Human<br>Subjects<br>Training<br>Completed | Submitted<br>Disclosure<br>Date |
| BSD 2.1 Determining the Review Requirements |              | Principal<br>Investigator                | PI First Name<br>PI Last Name | Biological<br>Sciences<br>Division | MED<br>Hematology<br>& Oncology  |           |         | 6/24/2022  | <u> </u>   | 9/15/2023                       |
| BSD 2.2 Purpose                             |              | Primary<br>Contact                       | Name                          | Biological<br>Sciences<br>Division | BSD Office<br>of Clinical<br>Res |           |         | 1/20/2015  |  |                                 |
| BSD 8.1<br>Supporting<br>Documents          |              | Co-<br>Investigator                      | Name<br>Last Name             | Biological<br>Sciences<br>Division | MED Pulm<br>& Critical<br>Care   |           |         | 7/23/2024  |  | 7/22/2024                       |
| BSD Final Page                              |              | Co-<br>Investigator                      | Name<br>Last Name             | Biological<br>Sciences<br>Division | NEU<br>Neurology                 |           |         |  | 1/31/2023  | 4/15/2024                       |
|   |              | Co-<br>Investigator                      | Name                          | Biological<br>Sciences<br>Division | PSY Adult<br>Psychiatry          |           |         | 8/28/2023  |  | 7/23/2024                       |
|   |              | Study<br>Coordinator                     | Name                          | Biological<br>Sciences<br>Division | BSD Office<br>of Clinical<br>Res |           |         | 3/11/2019  | 11/12/2013   |                                 |

Compensation

BSD 4.1 Study Population

Hello, **«** ■ Validate 🍇 Compare You Are Here: is Short title **▼** General Info and Staff Editing: IRB ◆ Go to forms menu 
→ Print ▼ Help 1.0 General Information 1.4 Funding Source **BSD 1.2** Research Team 1. \* Funding source(s): **Details** (Please check all that apply) **Internally Funded BSD 1.4 Funding Externally Funded/Supported** Source BSD 1.5 Study a. \* Check all external funding sources that apply: Locations United States Federal government agency/department State or local government agency/department **▼BSD Private foundation** Subcontract/subaward from another institution **BSD 2.1** Determining the Pharmaceutical company Review Other funding source Requirements b. \* Primary external funding source BSD 2.2 Purpose O To Be Determined Grant with Funding Proposals in AURA Grants (select on **BSD 3.1** next page) Recruitment and Contract or other agreement in ARTEMIS or Oncore Record Screening (select on next page) Clear BSD 3.2 Drugs 2. \* Who is the study sponsor? BSD 3.12 Data **UChicago PI** Collection **Other External Agency**  $\bigcirc$ BSD 3.13 Costs

Clear

Exit



Continue 🗪

2/4/2025, 4:01 PM

Save

Continue 😜

Hello, ■ Validate 🏂 Compare You Are Here: in Short title ▼ General Info and Staff Editing: IRB ◆ Go to forms menu 
→ Print ▼ Help 1.0 General Information 1.4.1 Funding Source (GRANTS) BSD 1.2 Research Team 1. \* Select your AURA Grant / FP Details Select... BSD 1.4 Funding Source Name PI Last Name PI First Name Sponsor Prime Grantee Status Submission Deadline There are no items to display BSD 1.4.1 **Funding Source** GRANTS 2. Is the purpose of this protocol submission only for the approval of an umbrella grant? BSD 1.4.3 Additional 3. If this study involves a grant, but the grant will not be uploaded to this submission, please provide the Funding Source protocol number under which that grant is approved. For example, if the grant funds multiple projects and has its own IRB number, such as the NCI Alliance grant. BSD 1.5 Study Locations 4. Upload Grant application **▼**BSD + Add **BSD 2.1** Determining the Name Review There are no items to display Requirements BSD 2.2 Purpose **BSD 3.1** Recruitment and Screening BSD 3.2 Drugs BSD 3.12 Data

BSD 3.2 Drugs BSD 3.12 Data

Hello, ■ Validate 🍄 Compare You Are Here: in Short title ▼ General Info and Staff Editing: IRB ◆ Go to forms menu 
→ Print ▼ Help 1.0 General Information 1.4.3 Additional Funding Source BSD 1.2 Research Team 1. Additional funding sources for study related expenses (study interventions, study drug/device provided at no Details cost, etc.). + Add BSD 1.4 Funding Source ID Name PI Last Name PI First Name Prime Grantee Status Submission Deadline Sponsor There are no items to display BSD 1.4.1 Funding Source GRANTS 2. Please list any other additional funding sources that are not associated with an FP in AURA Grants. BSD 1.4.3 Additional Funding Source BSD 1.5 Study Locations **▼BSD BSD 2.1** Determining the Review Requirements BSD 2.2 Purpose BSD 3.1 Recruitment and Screening


Continue 😜

2/4/2025, 4:09 PM

Save

Hello, **«** You Are Here: is short test title 2025 **▼** General Info and Staff Editing: IRB25-0004 ◆Go to forms menu ♣ Print ▼ Help 1.0 General 1.5 Study Locations Information 1. \* Select UChicago locations where this study will be conducted: **BSD 1.2** Research Team **Details** Location Name **BSD 1.4 Funding BSD/UCMC Campus** 3 Source 2. \* Is this a multi-site study? BSD 1.4.2 Yes No Clear **Funding Source ARTEMIS** 3. \* Are the UChicago researchers conducting this study or any portion of the study at a non-UChicago site (in the United States)? BSD 1.4.3 Yes No Clear Additional 4. \* Are the UChicago researchers conducting this study or any portion of the **Funding Source** study at an international site (outside the United States)? No Clear Yes **BSD 1.5 Study** Locations 5. Is another site asking the UChicago to be the IRB of record? No Clear **▼BSD** 6. Are you requesting that an outside IRB (not UChicago) to be the IRB of **BSD 2.1** record for this study? Determining the Yes No Clear Review Requirements BSD 8.1 Supporting **Documents BSD Final Page** 

Save Continue



Hello, ■ Validate AÃ Compare You Are Here: A Short title **▼** General Info and Staff Editing: IRB ◆ Go to forms menu 
→ Print ▼ ? Help 1.0 General Information 2.1 Determining the Review Requirements **BSD 1.2** 1. \* Dependent upon your research activities, consideration of this research Research Team may be required by other UChicago Committees. Please consider the **Details** research categories below and seek approval from the designated Committee if needed. Please select any applicable committees below. (Check all that apply) BSD 1.4 Funding Source None of these committees are required to the review this BSD 1.4.1 PRMC - Protocol Review and Monitoring Committee - $\Box$ **Funding Source** Includes patients with a cancer diagnosis, patients being **GRANTS** screened for cancer, cancer treatments or cancer therapies BSD 1.4.3 PBUC - Pathology Biospecimen Utilization Committee - $\Box$ Additional Use of diagnostic material for research purposes **Funding Source** CRC - Conducted within the Clinical Resource Center **✓** BSD 1.5 Study ISAP - Conducted with support of the UChicago Institute Locations  $\Box$ for Translational Medicine/CTSA **▼BSD** RADRAC - Radioactive Drug Research Advisory Committee -Reviews the use of radioactive drugs as well as the **BSD 2.1** purchase and use of radioisotopes in humans (including **Determining the** research and routine) Review Requirements IBC - Institutional Biosafety Committee - Reviews the  $\Box$ research use of biohazardous materials (examples include recombinant DNA, agents infectious to humans, animals or plants and other genetically altered organisms and agents) NRC - Nursing Research Committee - responsible for the П review of research proposals that are 1) Developed by nurses, 2) Involve UCM nursing employees as research participants, or 3) Involve additional resources to be provided by UCM nursing HIRO - Human Imaging Research Office - By checking this П box the HIRO office will be informed that you are conducting a human research study involving imaging. Other 2. \* What type of IRB review are you requesting? Full Board Review (at convened meeting) Expedited Review **Exempt Determination Not Human Subjects Research Determination** 

**Unsure/Do Not Know** 


Clear

Determination That Project is Not Research (including QI)

Exit

■ Save

Continue



#### **▼** General Info and Staff

1.0 General Information

BSD 1.2 Research Team Details

BSD 1.4 Funding Source

BSD 1.4.1 Funding Source GRANTS

BSD 1.4.3 Additional Funding Source

BSD 1.5 Study Locations

## **▼**BSD

BSD 2.1 Determining the Review Requirements a. \* If you believe that your protocol qualifies for exemption, select the category for which you believe it qualifies. The IRB must make the final determination regarding eligibility for exemption.

Note: To qualify for an exemption, the research must involve no more than minimal risk to subjects and must fall under at least one of the categories below. § 46.102(i) Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.

The BSD IRB has not recognized exempt categories 7 or 8.

(Choose ALL that apply)

Exempt
Category

Research, conducted in established or commonly accepted educational settings, which specifically involves normal educational practices that are not likely to adversely impact students' opportunity to learn required educational content or the assessment of educators who provide instruction. This includes most research on regular and special education instructional strategies, and research on the effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods.

Note: Access to student school records for research purposes without a FERPA exception, such as §99.31(a)(6), is not permitted unless the researchers have received prior permission from the student or student's legal guardian

Research studies do not qualify for this exemption category if the study is likely to adversely affect assessments of teachers or required learning materials for students is not equally provided in a classroom or students are not given materials they ought to have in order to succeed)

Exempt Category

Research that only includes interactions involving educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation of public behavior (including visual or auditory recording) if at least one of the following criteria is met. Please check each applicable box:

Note: Exemption category #2 is only applicable for children/minors under either c only if their in Save Continue



# **▼**BSD

BSD 2.1 Determining the Review Requirements

|                                     | educational tests or observation of<br>public behavior when the<br>researcher does not participate in<br>the activities observed - check the<br>box to see criteria details)   |
|-------------------------------------|--|
| Exempt<br>Sub-<br>Category<br>2.i   | The information obtained is recorded by the research team in such a manner that the identity of the human subjects cannot readily be ascertained, directly or through identifiers linked to the subjects.  |
| Exempt<br>Sub-<br>Category<br>2.ii  | Any disclosure of the human subjects' responses outside the research would not reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, educational advancement, or reputation. Disclosure of data will not be harmful to subjects or population groups.  |
| Exempt<br>Sub-<br>Category<br>2.iii | The information obtained is recorded by the research team in such a manner that the identity of the human subjects can readily be ascertained, directly or through identifiers linked to the subjects, and an IRB conducts a limited IRB review to make the determination required by the Common Rule at §46.111(a)(7). Please note that in order for the IRB to conduct a limited review additional information is required. Please select "Expedited Review" rather than "Exempt Determination" in View 2.1 of the AURA submission form and resubmit after answering all additional questions. |
| Exempt<br>Category<br>3             | Research involving benign behavioral interventions in conjunction with the collection of information from an adult subject through verbal or written responses (including data entry) or audiovisual recording if the subject prospectively agrees to the intervention and information collection.   |
|                                     | For the purpose of this provision, benign behavioral interventions are brief in duration, harmless, painless, not physically invasive, not likely to have a significant adverse lasting impact on the subjects, and the investigator has no reason to think the subjects will find the interventions offensive or embarrassing. Provided all such criteria are met, examples of such benign behavioral interventions would include having the subjects play an online game, having them solve puzzles under various noise conditions, or having them decide                                      |

conditions, or having them decide


Exit

■ Save

Continue 🗲

how to allocate

of received ca



1.0 General Information

BSD 1.2 Research Team Details

BSD 1.4 Funding Source

BSD 1.4.1 Funding Source GRANTS

BSD 1.4.3 Additional Funding Source

BSD 1.5 Study Locations

# **▼**BSD

BSD 2.1 Determining the Review Requirements

|                                     | themselves and someone else.  |
|-------------------------------------|---|
|                                     | If the research involves deceiving the subjects regarding the nature or purposes of the research, this exemption is not applicable unless the subject authorizes the deception through a prospective agreement to participate in research in circumstances in which the subject is informed that he or she will be unaware of or misled regarding the nature or purposes of the research.   |
|                                     | The protocol study must meet at least one of the following criteria:  |
| Exempt<br>Sub-<br>Category<br>3.i   | The information obtained is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained, directly or through identifiers linked to the subjects;  |
| Exempt<br>Sub-<br>Category<br>3.ii  | Any disclosure of the human subjects' responses outside the research would not reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, educational advancement, or reputation; or   |
| Exempt<br>Sub-<br>Category<br>3.iii | The information obtained is recorded by the investigator in such a manner that the identity of the human subjects can readily be ascertained, directly or through identifiers linked to the subjects, and an IRB conducts a limited IRB review to make the determination required by§46.111(a)(7). Please note that in order for the IRB to conduct a limited review additional information is required. Please select "Expedited Review" rather than "Exempt Determination" in View 2.1 of the AURA submission form and resubmit after answering all additional questions. |
| Exempt<br>Category<br>4             | Secondary research use of identifiable private information and identifiable bio specimens for which consent is not required, and if at least one of the following criteria is met:  |
| Exempt<br>Sub-<br>Category<br>4.i   | The identifiable private information or identifiable bio specimens are publicly available;  |
| Exempt<br>Sub-<br>Category<br>4.ii  | Information, which may include information about bio specimens, is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained directly or through identifiers linked to the subjects, the contact the subj   |



#### **▼** General Info and Staff

1.0 General Information

BSD 1.2 Research Team Details

BSD 1.4 Funding Source

BSD 1.4.1 Funding Source GRANTS

BSD 1.4.3 Additional Funding Source

BSD 1.5 Study Locations

#### **▼BSD**

BSD 2.1 Determining the Review Requirements Exempt Sub-Category

4.iv

The research is conducted by, or on behalf of, a Federal department or agency using government-generated or government-collected information obtained for non-research activities, if the research generates identifiable private information that is or will be maintained on information technology that is subject to and in compliance with section 208(b) of the E-Government Act of 2002, 44 U.S.C. 3501 note, if all of the identifiable private information collected, used, or generated as part of the activity will be maintained in systems of records subject to the Privacy Act of 1974, 5 U.S.C. 552a, and, if applicable, the information used in the research was collected subject to the Paperwork Reduction Act of 1995, 44U.S.C. 3501 et

will not re-identify subjects;

Category 5

seq.

Research and demonstration projects that are conducted or supported by a Federal department or agency, or otherwise subject to the approval of department or agency heads (or the approval of the heads of bureaus or other subordinate agencies that have been delegated authority to conduct the research and demonstration projects), and that are designed to study, evaluate, improve, or otherwise examine public benefit or service programs. including procedures for obtaining benefits or services under those programs, possible changes in or alternatives to those programs or procedures, or possible changes in methods or levels of payment for benefits or services under those programs. Such projects include, but are not limited to, internal studies by Federal employees, and studies under contracts or consulting arrangements, cooperative agreements, or grants. Exempt projects also include waivers of otherwise mandatory requirements using authorities such as sections 1115 and 1115A of the Social Security Act, as amended.

Each Federal department or agency conducting or supporting the research and demonstration projects must establish, on a publicly accessible Federal Web site or in such other manner as the department or agency head may determine, a I and demonsti



#### **▼** General Info and Staff

1.0 General Information

**BSD 1.2** Research Team Details

BSD 1.4 Funding Source

BSD 1.4.1 **Funding Source GRANTS** 

BSD 1.4.3 Additional **Funding Source** 

BSD 1.5 Study Locations

## **▼BSD**

**BSD 2.1 Determining the** Review Requirements

|                                    | the Federal department or agency conducts or supports under this provision. The research or demonstration project must be published on this list prior to commencing the research involving human subjects.   |
|------------------------------------|---|
| Exempt<br>Category<br>6            | Taste and food quality evaluation and consumer acceptance studies:  |
| Exempt<br>Sub-<br>Category<br>6.i  | If wholesome foods without additives are consumed, or   |
| Exempt<br>Sub-<br>Category<br>6.ii | If a food is consumed that contains a food ingredient at or below the level and for a use found to be safe, or agricultural chemical or environmental contaminant at or below the level found to be safe, by the Food and Drug Administration or approved by the Environmental Protection Agency or the Food Safety and Inspection Service of the U.S. Department of Agriculture. |

NOTE: Exempt category 4.iii is not permissible at this site.

b. \* Please provide the purpose and a brief description of the study. Please also clarify what role researchers at the UChicago will complete as part of this study and provide a rationale for the exempt category claimed for this research.

The justification must include how this study is minimal risk and a specific description of the procedure(s) involving the human subjects in sufficient detail to demonstrate that the research protocol meets the requirements for each category of exemption claimed for this protocol.

c. Please attach any documents that provide justification or support of the exempt category or categories listed above (e.g. protocol, data permissions, etc.). If you selected Exempt category 2 or 3, please ensure that all surveys and/or interviews scripts are uploaded, as well as any consent script(s) or form(s).


+ Add

Name

There are no items to display









**«** 

You Are Here: is short test title 2025

Editing: IRB25-0004 ◆Go to forms menu ♣ Print ▼





# Final Page

Please take this opportunity to review the information you have provided. It is very important that the responses in this protocol be thorough and specific. Failure to respond to all requested items, to submit required documents, or complete all personnel training will result in a delay in the review of this protocol and may result in the protocol being returned to the study team for correction or completion. Thank you for completing the information required to submit this IRB Study.

## THIS APPLICATION IS NOT YET SUBMITTED.

ONLY THE PRINCIPAL INVESTIGATOR (PI) of the protocol may submit the application for review. If you are the PI, you must click the SUBMIT activity on the study workspace to initiate the review of the submission.

## **▼** General Info and Staff

1.0 General Information

**BSD 1.2** Research Team Details

**BSD 1.4 Funding** Source

BSD 1.4.2 **Funding Source ARTEMIS** 

BSD 1.4.3 Additional **Funding Source** 

BSD 1.5 Study Locations

# **▼BSD**

00004

# Submit to IRB

## Submit to IRB

| 1.0   | submission as described, only with the approved principal investigator and, if any, co-investigator(s). All records maintained as required by the University of Chicago's policies and procedures.   | =                                |   |
|-------|--|----------------------------------|---|
|       | In addition, I agree to the responsibilities of a PI, per University guidelines, including:  Obtaining informed consent (if applicable) from all subjects as outlined in the submission.  Reporting Unanticipated Problems to the IRB per the IRB Unanticipated Problem reporting policy.  Obtaining renewal of the protocol prior to the expiration of the approval period or halt all study activities upor Accepting ultimate responsibility for the protection of the rights and welfare of human subjects, conduct of the performance of the project.  Performing all research activities by qualified personnel according to the IRB approved submission.  Ensuring that research personnel have or will receive appropriate training.  No changes will be made in the protocol or consent form until approved by the IRB. |                                  |   |
| 2.0   | Enter comments below, if applicable:   |                                  |   |
| 3.0   | * Does the work proposed involve any data, materials, drugs or devices from a company in which you hat the case of a corporate sponsor have you received any payments, stock or equity from this sponsor in the Yes No Clear   |                                  | Link to policy: UChicago<br>COI Policy  |
| 4.0   | To the best of your knowledge, is the work described in this proposal related to an outside financial inter or Other Research Personnel?  Yes No Clear   | rest of any Co-Investigators     |   |
| 5.0   | If yes to question 3 or 4, please describe below or attach a memo or letter to explain to the IRB Committee the specific study being proposed.   | ee the conflict as it relates to | Note that this memo will be accessible to all members of the research team. If you do not wish all members of the research team to have access to this memo, please send it to the IRB administrator assigned to this submission (after this study has been submitted) as an email. |
|       | + Add  |                                  |   |
|       | Name   |                                  |   |
|       | There are no items to display  |                                  |   |
| 6.0   | If yes to question 3 or 4, has this conflict of interest been disclosed to University Research Administration  Yes No Clear  | on (URA)?                        |   |
|       | If yes, note IRB has access to the final management plan and will consult this plan when reviewing this study.   |                                  |   |
|       | If no, contact URA to disclose this conflict.  |                                  |   |
| Click | k OK to submit to the IRB for review. Click Cancel to return.  |                                  |   |
|       |  |                                  |   |
|       |  |                                  |   |